Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient
- PMID: 29225856
- PMCID: PMC5715418
- DOI: 10.1002/ccr3.1256
Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient
Abstract
Piperacillin-tazobactam is one of the most common causes of drug-induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life-threatening piperacillin-tazobactam-associated DIIHA in a 30-year-old woman with CF and propose management recommendations for piperacillin-tazobactam-associated DIIHA in CF patients.
Keywords: Anemia; cystic fibrosis; hemolysis; piperacillin; tazobactam.
References
-
- Garratty, G. 2010. Immune hemolytic anemia associated with drug therapy. Blood Rev. 24:143–150. - PubMed
-
- Mayer, B. , Yürek S., and Salama A.. 2010. Piperacillin‐induced immune hemolysis: new cases and a concise review of the literature. Transfusion 50:1135–1138. - PubMed
-
- Waters, V. , and Ratjen F.. 2015. Pulmonary Exacerbations in Children with Cystic Fibrosis. Ann. Am. Thorac. Soc. 12(Suppl. 2):S200–S206. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources